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1. Introduction
Consider a randomized, two-arm, placebo-controlled clinical trial to evaluate eÆcacy of
a preventive HIV vaccine. The rst two trials of this kind began in 1998 and 1999, and
are ongoing (Francis et al., 1998). For each trial, the primary objective is to assess the
vaccine's impact on the incidence of HIV infection (Rida and Lawrence, 1995). Another
objective of these trials and future trials is to assess the vaccine's impact on viral load
post acquisition of HIV (Nabel, 2001); viral load is the concentration of HIV in blood or
another body compartment. This objective is important because natural history studies
have shown that the viral load of an infected person predicts infectiousness (Quinn et al.,
2000) and the rate of disease progression (cf., Mellors et al., 1997), and several animal
studies have identied vaccines that failed to prevent infection but successfully controlled
viremia and prevented disease (cf., Shiver et al., 2002). Therefore, a vaccine eect to
lower viral load may be benecial, whereas an eect to increase viral load may hasten or
exacerbate disease. The risk of harmful vaccine \enhancement" of viral load is genuine
(Burke, 1992), and has been observed for several viral vaccines (cf., Mascola et al., 1992).
The impact of vaccination on viral load can be studied in several ways. The data
available for analysis are right-censored HIV infection diagnosis times in all randomized
subjects, and longitudinal quantitative measurements of viral load in subjects who become
infected. Two main inferential approaches are intent-to-treat (ITT) analyses of all ran-
domized subjects and conditional analyses of infected subjects only. The ITT approach
assesses the causal eect of randomizing to vaccine. However, the majority (likely > 80%)
of randomized subjects will have zero viral load because they do not become infected dur-
ing the trial, which can give ITT analyses low power for detecting many alternatives of
interest (Hudgens, Hoering, and Self, 2002a). Also, in ITT analyses two very dierent
populations (uninfected and infected subjects) are placed on the same response scale.
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Consequently, the ITT analysis of viral load assumes that the outcomes absence of infec-
tion (with zero viral load) and infection with viral load below the quantication limit of
the assay are approximately equally prognostic for disease progression. This assumption
is diÆcult to justify, because the initial suppression of viral load in infected subjects may
be lost due to HIV evolution (Barouch et al., 2002). Alternatively, rank-based ITT meth-
ods could be used that assign the lowest two ranks to absence of infection and viral load
below the assay limit, respectively. However, to achieve greater power and to study the
causal eect of randomizing to vaccine in a subpopulation of persons who would become
infected described below, in this article we consider conditional analyses.
Conditioning on infection poses a major challenge to making an unbiased inference
of the vaccine eect on viral load, because the analyzed groups are selected by the post-
randomization event HIV infection. This post-treatment selection bias problem is common
in biomedical studies (cf., Rosenbaum, 1984; Robins and Greenland, 1992), and implies
that a comparison of viral load between infected subgroups, which measures the `net
vaccine eect', does not have a causal interpretation. In particular, partial eÆcacy of
the vaccine to prevent HIV infection can bias the viral load comparison. For example,
the vaccine may prevent infections in individuals with strong immune systems, but allow
infections in individuals with relatively weak immune systems. If a weaker immune system
correlates with a higher viral load upon infection, then the viral loads in infected subjects
will tend to be selectively shifted upwards in vaccine relative to placebo recipients. On the
other hand, selection bias could occur in the opposite direction, for example the vaccine
could protect well against highly virulent strains but allow infections with mild viruses
which establish low viremia levels. Therefore, a standard two-sample test comparing viral
loads between infected groups may give a misleading impression that vaccination enhances
or suppresses viral burden. Or, the test may fail to detect a meaningful vaccine eect.
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Frangakis and Rubin (2002) (FR) developed a framework for causal inference that can
be used for studying a causal eect of vaccine on viral load that adjusts for the post-
randomization selection bias. This framework denes causal estimands using potential
outcomes (Rubin, 1974, 1978; Holland, 1986). For the present problem, each trial partici-
pant has a potential infection status under each randomization assignment. Additionally,
subjects who would be infected under randomization to vaccine have a potential viral load
under vaccine assignment, and subjects who would be infected under randomization to
placebo have a potential viral load under placebo assignment. Within FR's framework,
a causal vaccine eect on viral load is dened as a comparison of potential viral loads
under the two randomization assignments for a subgroup of subjects with a common pair
of potential infection status outcomes; FR referred to such a group as a principal stratum.
Hudgens, Hoering, and Self (2002b) (HHS) developed tests for a causal vaccine eect
on viral load in the \always infected" principal stratum of subjects who would be infected
regardless of randomization to vaccine or placebo. Under plausible assumptions described
in Section 2, vaccine recipients who become HIV infected would also be infected had they
received placebo. Consequently, inferences drawn for the always infected subpopulation
address a practical question for individuals vaccinated in a public health program: If I
acquire HIV despite vaccination, what is the viral load compared to if I had foregone
vaccination? We consider inference on causal estimands dened for the always infected
principal stratum, which are dened in terms of potential outcomes in Section 2.
The causal estimands are not identied, because membership of an infected placebo
recipient in the always infected principal stratum is unknown (i.e., the infection status
had the subject been randomized to vaccine is unknown). This problem can be addressed
by modeling the probability that an infected placebo recipient is in the always infected
stratum as a function of the potential viral load under randomization to placebo. HHS
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implicitly took this approach, by dening two selection models that express bounds for
the maximum plausible levels of selection bias. Under these models, which identify the es-
timands, HHS developed testing procedures for assessing dierences in the potential viral
load distributions of always infected subjects under the two randomization assignments.
Testing the null hypothesis presuming an extreme degree of selection bias is practically
very useful, because rejection implies a signicant eect of vaccination above and beyond
any plausible selective eects. However, the actual degree of bias is likely less than that
specied by an extreme model, so that HHS's tests may sacrice power. Achieving maxi-
mal power is especially important for key subgroup analyses, such as by gender (Sterling
et al., 2001), route of exposure, or host genotype, and for analyses of seminal viral load,
given the higher variability of seminal versus plasma viral load (Coombs et al., 1998).
Therefore, it is important to also consider selection models that reect intermediate de-
grees of selection bias, which may be more realistic and will allow for more powerful
statistical tests. In this article we develop a method for sensitivity analysis that con-
siders a continuous range of possible selective eects spanning from no bias to maximal
plausible bias as considered by HHS. In dierent contexts, Rosenbaum and Rubin (1983),
Scharfstein, Rotnitzky, and Robins (1999), and Goetghebeur et al. (2000) also developed
methods of continuously-indexed sensitivity analysis of inferences on causal eects.
The article is organized as follows. Section 2 denes causal estimands and shows that
they are identied from three assumptions and a biased sampling model that species
the nature and degree of selection bias. A class of logistic biased sampling models is de-
scribed, which is indexed by an interpretable sensitivity parameter  that can be chosen
to represent any magnitude of selection bias ranging between extreme positive and nega-
tive bias. Given a particular model in the class, Section 3 describes procedures for testing
the corresponding null hypothesis of no causal eect of vaccination on viral load. A plot
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of the test statistic (or p-value) versus  provides a sensitivity analysis to help discern if
the data support a causal eect that is robust to plausible post-randomization selective
eects. Section 3 also shows how the sensitivity analysis can be based on estimation
rather than testing. Section 4 evaluates the proposed testing procedures in simulations,
and Section 5 illustrates a sensitivity analysis on a simulated vaccine trial dataset.
2. Causal Estimands and Biased Sampling Models for Sensitivity Analysis
2.1 Denition and identiability of causal estimands
First we dene the potential outcomes of the trial participants. Let Z be the vector
of vaccination assignments for the N randomized subjects, with i
th
element Z
i
(Z
i
= v;
vaccine; Z
i
= p; placebo). Let S(Z) be the N -vector with ith element S
i
(Z), which is
the indicator of whether the i
th
subject would be infected given Z. For subjects with
S
i
(Z) = 1; let Y
i
(Z;S) be the potential viral load (PVL) given Z and S = S(Z). In order
to limit the possible potential outcomes for each subject, we adopt Rubin's (1978) Stable
Unit Treatment Value Assumption (SUTVA) throughout. It states that S
i
(Z) = S
i
(Z
0
)
whenever Z
i
= Z
0
i
, and, Y
i
(Z;S) = Y
i
(Z
0
;S
0
) whenever Z
i
= Z
0
i
and S
i
(Z
i
) = S
0
i
(Z
i
) = 1:
SUTVA implies that potential outcomes for each subject i are unrelated to the assignment
Z
j
of other subjects, and allows S
i
(Z) and Y
i
(Z;S) to be written as S
i
(Z
i
) and Y
i
(Z
i
);
respectively. Therefore, under SUTVA each subject has two potential infection outcomes
(S
i
(v), S
i
(p)) and at most two PVL outcomes (Y
i
(v); Y
i
(p)). For each subject only one
of S
i
(v) or S
i
(p) is observed, denoted S
obs
i
 S
i
(Z
i
); and in the subgroup with S
obs
i
= 1;
Y
obs
i
 Y
i
(Z
i
) is observed. Note that Y
i
(v)(Y
i
(p)) is dened only if S
i
(v) = 1(S
i
(p) = 1):
By Property 2 of FR, a comparison between the ordered sets fY
i
(v) : S
i
(v) = S
i
(p) =
1g and fY
i
(p) : S
i
(v) = S
i
(p) = 1g is a causal eect, because it is made within a principal
stratum. For subjects in the always infected stratum fS
i
(v) = S
i
(p) = 1g, suppose the
Y
i
(v) are identically distributed as F
alw:inf
(v)
(); and the Y
i
(p) are identically distributed as
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Falw:inf
(p)
(): Then, any functional that measures a contrast of the distributions
F
alw:inf
(v)
(y)  Pr(Y
i
(v)  yjS
i
(v) = S
i
(p) = 1)
F
alw:inf
(p)
(y)  Pr(Y
i
(p)  yjS
i
(v) = S
i
(p) = 1) (1)
is a causal estimand. Based on (1), a null hypothesis for no causal eect of vaccination
on viral load in the always infected principal stratum can be expressed as:
H
0
: F
alw:inf
(v)
(y) = F
alw:inf
(p)
(y) for all y: (2)
Unfortunately, because neither distribution in (1) is identiable (since S
i
(v) and S
i
(p)
are not both observed for any subject), it is not possible to test (2) without introducing
assumptions. Two assumptions are useful for identifying the distributions:
A1: The assignment Z
i
of each subject is independent of his/her potential outcomes.
A2: For each subject i, Pr(S
i
(v) = 1; S
i
(p) = 0) = 0:
Assumption A1 plausibly holds in HIV vaccine eÆcacy trials due to randomization and
blinding. A2 states that no subject would be infected if randomized to vaccine but unin-
fected if randomized to placebo, and under A1 will hold if vaccination does not increase
the per-exposure infection probability for any subject. The SUTVA assumption may not
hold because HIV disease is infectious (Halloran and Struchiner, 1995); however if the
study population is a small sample from a large population of susceptible individuals and
there are few infectious contacts between trial participants, then it should approximately
hold. SUTVA can be checked through epidemiologic studies and data on mixing of risk
behavior among trial participants. Given SUTVA, A1 can be tested based on risk behav-
ior data, and under SUTVA and A1, A2 can be checked by testing if the HIV infection
rate is higher in the vaccine group than in the placebo group.
Assumption A2 is very useful, because it implies that infected vaccine recipients
must be in the always infected principal stratum. Together with A1, this implies that
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Falw:inf
(v)
(y) = F
v
(y) Pr(Y
obs
i
 yjS
obs
i
= 1; Z
i
= v); where F
v
() is the distribution of viral
load in infected vaccine recipients; thus F
alw:inf
(v)
() is identied from the observed data.
A2 is similar to Angrist, Imbens, and Rubin's (1996) Monotonicity Assumption 5, which
is useful for identifying a causal estimand dened for a principal stratum of compliers.
On the other hand, A1 and A2 do not identify F
alw:inf
(p)
(); because they do not determine
whether an infected placebo recipient is in the \protected" fS
i
(v) = 0; S
i
(p) = 1g or
always infected fS
i
(v) = 1; S
i
(p) = 1g stratum.
Given the randomization assignment and observed infection status of a trial partic-
ipant, Table 1 indicates the principal stratum or strata to which the participant must
belong, and lists the information available on potential viral loads. The table makes clear
that the always infected stratum is the natural subpopulation for causal inference on viral
load, because it is the only stratum for which causal estimands involve only well-dened
potential viral loads. Rubin (2000) made this point through a parallel example in which
there are two randomized treatments and vital status is observed one year after random-
ization, and the goal of causal inference is to assess the treatment eect on quality of life
within the principal stratum of subjects alive under either treatment assignment.
2.2 Logistic selection bias models that identify the causal estimands
The set of subjects infected under randomization to placebo, fS
i
(p) = 1g, partitions
into the principal strata of protected and always infected subjects, with the level of vaccine
eÆcacy (V E) against infection determining the proportion in each. Specically, dene
V E = 1 RR = 1 Pr(S
i
(v) = 1)=Pr(S
i
(p) = 1); V E is a causal estimand measuring the
relative reduction in infection risk conferred by randomizing to vaccine versus placebo.
A2 implies V E = Pr(S
i
(v) = 0jS
i
(p) = 1); which is the probability that a subject in
fS
i
(p) = 1g is in the protected principal stratum (note that A2 is crucial here; Pr(S
i
(v) =
0jS
i
(p) = 1) is not identied by randomization alone). The density of Y (p) in subjects
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infected under randomization to placebo (f
(p)
(y)) can be written as a mixture of the
densities of Y (p) for the protected (f
prot
(p)
(y)) and always infected (f
alw:inf
(p)
(y)) strata:
f
(p)
(y) = V E  f
prot
(p)
(y) + (1  V E)  f
alw:inf
(p)
(y): (3)
With some calculations, the mixture (3) can be re-expressed as a biased sampling model
f
alw:inf
(p)
(y) =W
 1
w(y)f
(p)
(y); (4)
where w(y) = Pr(S
i
(v) = 1jY
i
(p) = y; S
i
(p) = 1) and W =
R
1
 1
w(y)f
(p)
(y)dy is a
normalizing constant equal to 1   V E = RR: The weight function w(y) = RR(y) =
1   V E(y) is the probability that a subject infected with viral load y if randomized to
placebo would be infected if randomized to vaccine.
Let F
p
(y) and f
p
(y) be the distribution and density of the observed viral load in in-
fected placebo recipients, respectively. Under the randomization assumption A1, F
(p)
(y) =
F
p
(y), and the biased sampling model (4) can be re-stated as f
alw:inf
(p)
(y) = (1 V E)
 1
w(y)
f
p
(y): Therefore, under A1-A2 the null hypothesis of interest (2) is equivalent to
H
0
: F
v
(y) = (1  V E)
 1
Z
y
 1
w(z)dF
p
(z) for all y: (5)
By A1, V E is identied from the observed data. If w() were known, then both
F
alw:inf
(v)
() and F
alw:inf
(p)
() would be identied, and the hypothesis (2) could be tested.
However, w() is unknown, and it is not possible to test whether a particular w() is
correctly specied from the data plus A1-A2. Our approach to this problem assumes w()
is known, and tests (5) for a variety of xed choices of w(). For such an approach to be
fruitful, it is important that the unidentied sensitivity function w() be interpretable.
Towards this goal, we parameterize w(y) as logistic, indexed by an interpretable selec-
tion bias parameter , which allows it to be constant or smoothly monotone increasing or
decreasing: w(y) = w(yj; ) = expf+yg=(1+expf+yg): The sensitivity parameter
9
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 is a log odds ratio: e

is the odds ratio of infection under randomization to vaccine given
infection under randomization to placebo with viral load y versus with viral load y   1.
This interpretation allows the choice of  to be guided by beliefs about plausible degrees
of selection bias. For xed  2 [ 1;1], the logistic selection bias model is specied by
F
alw:inf
(p)
(y) = (1  V E)
 1
Z
y
 1
expf + zg
1 + expf+ zg
dF
p
(z)  F
p
(yj): (6)
Given xed , the parameter  is determined as the solution to the equation F
p
(1j) = 1:
Figure 1 illustrates ve selection models specied by (6) and  xed at 1; 1; 0; 1;1;
which represent dierent ways to distribute V E of the mass of f
(p)
(y) into the protected
principal stratum via (3). Note that if V E = 0 there is no selection bias, regardless of
; and the higher V E; the greater opportunity for bias. Heuristically,  species how
much bias occurs through V E: Fixing  = 0 species a constant weight w(yj;  = 0) =
RR; and reects an assumption of no selection bias. Fixing  > 0 makes w(yj; )
monotone increasing in y and reects \positive" selection bias, with infection odds under
randomization to vaccine higher for a larger PVL Y (p) = y. In this case, if the causal null
hypothesis (2) is true, then the net vaccine eect is that F
v
() is stochastically larger than
F
p
(): Similarly,  < 0 makes w(yj; ) monotone decreasing in y and reects \negative"
selection bias, with infection odds under randomization to vaccine lower for a larger y,
and under (2) the net vaccine eect is that F
v
() is stochastically smaller than F
p
():
HHS developed tests for (5), using two models representing maximum plausible posi-
tive and negative bias. HHS's \positive" selection model is specied by placing all subjects
in fS
i
(p) = 1g with Y (p) less than the V E
th
-percentile q
V E
(p)
of its distribution into the
protected principal stratum, and the \negative" selection model is specied by placing
all subjects in fS
i
(p) = 1g with Y (p) greater than the upper V E
th
-percentile q
1 V E
(p)
of
its distribution into the protected principal stratum. These models are limiting members
of the class of logistic models (6), specied respectively by  = 1 (Figure 1, right-most
10
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panel) and  =  1 (Figure 1, left-most panel). To see this, note that setting  =  q
V E
(p)
implies lim
!1
w(yj; ) equals Ify > q
V E
(p)
g for y 6= q
V E
(p)
and 1=2 for y = q
V E
(p)
; and setting
 =  q
1 V E
(p)
implies lim
! 1
w(yj; ) = Ify < q
1 V E
(p)
g for y 6= q
1 V E
(p)
and 1=2 for
y = q
1 V E
(p)
. Therefore, based on the logistic weight function with  ranging between  1
to 1; the class of models (6) spans all plausible magnitudes of selection bias.
If selection bias is presumed to follow model (6) for some unknown  within a plausible
range 
neg
to 
pos
, then a 2-sided null hypothesis representing no causal vaccine eect in
the always infected stratum allowing for possible selection bias is given by
H
0
pos
;neg
: F
p
(j
pos
)  F
v
()  F
p
(j
neg
); 
pos
2 [0;1]; 
neg
2 [ 1; 0]: (7)
Under A1-A2, H
0
pos
;
neg
is equivalent to F
alw:inf
(p)
()  F
alw:inf
(v)
() assuming model (6) with
 = 
pos
and F
alw:inf
(v)
()  F
alw:inf
(p)
() assuming model (6) with  = 
neg
. For the special
case 
pos
= 
neg
= 0, (7) collapses to the null hypothesis of no net vaccine eect on
viral load, H
0
: F
v
() = F
p
(): Therefore, under the assumption of no selection bias, a
standard comparison of viral load distributions between infected subgroups assesses the
causal eect of vaccine in the always infected principal stratum.
One-sided null hypotheses representing no causal vaccine eect are given by
H
0
pos
: F
p
(j
pos
)  F
v
(); 
pos
2 [0;1]; (8)
H
0
neg
: F
v
()  F
p
(j
neg
); 
neg
2 [ 1; 0]: (9)
If (8) is rejected, then always infected individuals have signicantly higher viral loads
under randomization to vaccine than placebo when controlling for selection bias. In
sum, A1-A2 and model (6) can be used to specify a 1- or 2-sided null hypothesis for no
causal eect of vaccine in the always infected stratum that can be tested, and a sensitivity
analysis can be performed by testing the hypothesis for a range of xed values of 
pos
; 
neg
:
3. Statistical Hypothesis Tests and Estimation
11
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Let Y
v1
;    ; Y
vn
v
and Y
p1
;    ; Y
pn
p
denote the samples of observed viral loads from in-
fected vaccine and placebo recipients. Y could be the average of 2 or more viral load
measurements taken from an infected subject, or another continuous outcome such as the
area under the longitudinal viral load curve. We assume each sample is independently,
identically distributed, and the two samples are independent of one another. Sections 3.1
and 3.2 consider nonparametric tests of the null hypotheses (7), (8), and (9), and Section
3.3 considers nonparametric estimation of an average causal eect parameter.
3.1 Nonparametric Test Statistics
Fix 
pos
 0 and 
neg
 0. Using the empirical distributions
b
F
v
and
b
F
p
calculated from
the two observed samples, and an estimate of V E; nonparametric tests of H
0
pos
; H
0
neg
;
and H
0
pos
;
neg
can be based on comparisons of
b
F
v
() with
b
F
p
(j
pos
);
b
F
p
(j
neg
); and both
estimates, respectively. The V E parameter can be estimated by
d
V E = 1 
n
v
N
v
=
n
p
N
p
, with
N
v
(N
p
) the number of subjects randomized to vaccine (placebo). Under A1
d
V E is unbi-
ased for V E if the vaccine protects by an \all-or-none" mechanism, and is approximately
unbiased if it protects by another mechanism, since HIV infection is a rare event (Hal-
loran, Haber, and Longini, 1992). We consider three criterion functions for summarizing
the comparisons, based on means, suprema, and integrated squared dierences.
The statistic T
M
for comparing means, appropriate for testing (8) or (9), is given by
T
M
=
Z
1
 1
y
n
d
b
F
v
(y)  d
b
F
p
(yj)
o
; (10)
where
R
1
 1
yd
b
F
v
(y) = n
 1
v
P
n
v
i=1
Y
vi
and
b
F
p
(yj) is the nonparametric maximum likelihood
estimator of F
p
(yj) under model (6), calculated as
b
F
p
(yj) =

1 
d
V E

 1
1
n
p
n
p
X
i=1
I fY
pi
 ygw(Y
pi
j
b
; ):
Here,
b
 is computed by solving the equation
b
F
p
(1j) = 1 for ; i.e.,  solves
1 
d
V E =
Z
1
 1
expf + yg
1 + expf+ yg
d
b
F
p
(y): (11)
12
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A solution to (11) can be found rapidly using a numerical one-dimensional line search.
The null hypothesis H
0
pos
is rejected if T
M
pos
is large. For large positive 
pos
and
b
 =  
pos
b
q
c
V E
p
; with
b
q
c
V E
p
the (n
p
(1  
d
V E))
th
largest value of Y
p1
;    ; Y
pn
p
as used by
HHS, T
M
pos
reduces to HHS's nonparametric statistic T
M
that tests (8) with 
pos
= 1:
Similarly, H
0
neg
is rejected if T
M
neg
is negative and large, and for large negative 
neg
and
b
 =  
neg
b
q
1 
c
V E
p
; T
M
neg
reduces to HHS's statistic T
M
that tests (9) with 
neg
=  1:
The maximum of jT
M
pos
j and jT
M
neg
j can be used for a 2-sided test of (7).
Second, a 1-sided Kolmogorov-Smirnov-type statistic for testing (8) is dened by
T
KS
pos
= m
1=2
sup
 1<y<1



n
b
F
p
(yj
pos
) 
b
F
v
(y)
o
_ 0


 ; (12)
with n = n
v
+ n
p
; m = (n
v
n
p
)=n; and an Anderson-Darling-type statistic is dened by
T
AD
pos
= m
Z
1
 1
hn
b
F
p
(yj
pos
) 
b
F
v
(y)
o
_ 0
i
2
c
H
n
(yj
pos
)

1 
c
H
n
(yj
pos
)

d
c
H
n
(yj
pos
); (13)
where
c
H
n
(yj
pos
) = (n
p
=n)
b
F
p
(yj
pos
) + (n
v
=n)
b
F
v
(y): One-sided statistics for testing (9)
are given by (12) and (13) with 
pos
replaced by 
neg
and _ replaced by ^: Two-sided
statistics for testing (7) can be dened similarly. When  = 
pos
= 
neg
= 0; the 2-sided
statistics reduce to the classical Kolmogorov-Smirnov and Anderson-Darling test statistics
for comparing two distribution functions (D'Agostino and Stephens, 1986).
3.2 Computing Critical Values for the Tests
We use a modication of the `Controls Only' bootstrap procedure developed by HHS
for computing critical values for the test statistics. The modication is that once the
bootstrap estimate of vaccine eÆcacy
d
V E
?
is computed as in HHS, a bootstrap estimate
b

?
is computed as the solution to equation (11) with
d
V E replaced by
d
V E
?
: Estimating
V E and  within each bootstrap iteration appropriately accounts for the uncertainty in
the vaccine eÆcacy estimate.
13
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In general, the nonparametric bootstrap tends to approximate smooth distributions
better than distributions with discontinuities. For  nite, the use of a smooth logistic
selection weight function in the test statistics suggests that the nonparametric bootstrap
should perform well. For jj innite (the extreme cases), the distributions F
p
(j
pos
) and
F
p
(j
neg
) have discontinuities at the truncation point, which could abrogate bootstrap
performance. The simulation study conrms that tests of H
0
pos
with 
pos
= 1 have
poorer size and power characteristics than tests of H
0
pos
with 
pos
= 1:
3.3 Nonparametric Estimation
Under A1-A2 and a model (6) with  xed,
b

ACE
()   T
M
is a consistent es-
timate of the average causal eect (ACE) parameter 
ACE
() =
R
1
 1
yfdF
alw:inf
(p)
(y)  
dF
alw:inf
(v)
(y)g: By bootstrap re-sampling from
b
F
v
(y) and
b
F
p
(yj), 95% bootstrap percentile
condence intervals about 
ACE
() can be constructed. An estimation-based sensitivity
analysis can be carried out by plotting point and interval estimates of 
ACE
() versus .
4. Simulation Study
Through simulations of an HIV vaccine trial we evaluate the three 1-sided tests of the
null hypothesis H
0
pos
in (8). Rejecting (8) implies that individuals infected under ei-
ther assignment have signicantly higher viral load if assigned vaccine than if assigned
placebo when controlling for selection bias specied by 
pos
and model (6). We consider
an intermediate-sized eÆcacy trial with 45 infections expected in the placebo group (Rida
et al., 1997), and suppose the true V E equals 30% or 50%. The true amount of selection
bias is determined by the parameter  = 
pos
in model (6), with  = 0; 1, or 1: Thus,
data are generated under three kinds of null models, which assume no selection bias, an
intermediate amount of selection bias (supposing the infection odds under vaccine of a
subject who would be infected under placebo increases e
1
= 2:72-fold per one unit higher
PVL Y (p)), and maximal plausible positive selection bias. We assume two independent
14
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measures of viral load are available per person. The sample Y
p1
;    ; Y
pn
p
is generated from
a normal distribution with mean 4.50 and variance 0.36. These parameter values equal
those used by HHS, selected based on a cohort of recently HIV infected persons. The
sample Y
v1
;    ; Y
vn
v
is generated from F
p
(j) in model (6) with true  = 0; 1; or 1: For
each true ; three vaccine eects on viral load in the always infected are evaluated: mean
shifts of  = 0; 1=3; or 1=2 log
10
over and above any selection bias induced by the true ;
i.e., the samples are drawn such that F
alw:inf
(p)
(y) = F
p
(yj) and F
alw:inf
(v)
(y) = F
p
(y j).
For each of 500 datasets simulated under each parameter conguration, the three 1-
sided test statistics are calculated, with presumed selection bias levels  = 0, 1, or 1.
Critical values for the tests are determined using 500 bootstrap replications.
Using a nominal 5% Type I error level, Table 2 shows estimated sizes and powers of the
tests. The sizes are judged by the bolded rows, for which the correct amount of selection
bias is presumed (true  = presumed ). All tests have empirical size close to nominal,
except when V E = 30% and  = 1 the size is inated to 8-12%. The elevated size is
caused by the simulated trials with estimated V E less than zero; this occurred 18 times
and of these the nonparametric mean-based test rejected the null hypothesis 16 times. If
the 18 trials with
d
V E < 0 are discarded, then the rejection rate is 5.8%. A similar pattern
was seen for the other test statistics. When
d
V E < 0; the testing procedure operates under
the assumption of no selection bias, and simply tests H
0
: F
v
() = F
p
(). However, in fact
F
v
() < F
p
() due to positive selection bias (true  = 1), which explains the inated
probability of rejection. Note that when V E = 50% the sizes are not elevated, because
the estimated V E is rarely negative. In summary, the tests generally have nominal size,
except that when V E is low and the sample size is moderate, underestimation of V E can
lead to an increased risk of false rejection. This phenomenon was also found by HHS.
When the correct selection bias model is assumed, the three tests have comparable
15
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power, with that of the Kolmogorov-Smirnov procedure slightly less. In addition, power
diminishes as the true  increases. Next we consider power when an incorrect amount of
selection bias is presumed (Table 2, unbolded rows). If zero bias is presumed ( = 0), but
in truth there is moderate bias ( = 1), power is high, but at the expense of an inated
false rejection rate, at 15% when V E = 30% and 26% when V E = 50%. If zero bias
is presumed and there is actually extreme bias ( = 1), then power is extremely high
and the sizes are extremely inated. This illustrates the importance of accounting for
the possibility of selection bias to avoid being misled. Next, suppose there is no selection
bias, but one conservatively presumes  = 1: Then power drops severely, e.g., to 10%
for detecting a 1/2 log
10
mean shift when V E = 50%; compared to 93% if the correct
 = 0 is assumed. For the more moderate assumption  = 1; a much smaller price is
paid, with power dropping to 64%. Thus, making a highly conservative assumption of
maximal selection bias can cause great power loss. This nding supports the use of a
continuously-indexed sensitivity analysis as proposed here.
The Kolmogorov-Smirnov-type and Anderson-Darling-type tests are expected to have
greater power than the mean-based test for detecting non-mean-shift alternatives. We
briey studied this conjecture by generating placebo group viral loads from a normal
mixture distribution 0:5N(3:50; 0:36) + 0:5N(5:50; 0:36) (e.g., infection with a mild or
virulent virus), and vaccine group viral loads from a mixture of truncated normal dis-
tributions 0:5TruncN(3:50; 0:36) + 0:5TruncN(5:50; 0:81), with truncation point of each
distribution at the 70
th
percentile. With alternative hypothesis no change in the rst
component and a 1.5 log
10
mean shift in the second component, assuming  = 1; the
Kolmogorov-Smirnov-type test had 78% power while the other tests had between 13%
and 20% power. Thus, if the viral load distributions are expected to dier in respects
other than a mean-shift, then the Kolmogorov-Smirnov-type test may be preferable.
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5. Example
To illustrate how a sensitivity analysis could be carried out on a forthcoming vaccine trial
dataset, we analyze a single dataset, simulated using Gaussian distributions assuming
n
p
= 45 infections in the placebo group,
d
V E = 40% (and thus n
v
= 27 infections in the
vaccine group), a true causal vaccine eect to reduce the mean viral load in the always
infected by 0:33 log
10
, and true  = 
neg
=  1, i.e., moderate negative selection bias
that leads to lower viral loads in infected vaccine recipients. The true causal and biasing
vaccine eects on viral load imply that the net vaccine eect on mean viral load is 0.49
log
10
. For 
neg
ranging in [ 1; 0], we consider testing H
0
neg
in (9) versus the alternative
hypothesis that vaccination lowers viral load in the always infected.
The rst step is to produce descriptive plots and summary measures comparing the
observed viral load distributions between the infected subgroups. The average viral loads
are 3.96 and 4.48 in the infected vaccine and placebo groups, respectively. The second step
is to calculate a test statistic for values of  = 
neg
ranging between 0 and a negative value
that makes the selection bias odds ratio OR = e
 
large (e.g.,  =  5 yields e
 
= 148),
and for the extreme model ( =  1): The third step is to plot the p-value of the test
statistic versus OR, which will always be monotone except for stochastic variations in the
bootstrap. This provides a graphical sensitivity analysis (Figure 2). Fourth, calculation
of the value of  at which the test statistic is exactly statistically signicant at the 0.025
level allows one to assess the extent of selection bias needed to lose the signicance of the
result. A 0.025 signicance level is chosen because the test is 1-sided. In this example
the critical  value for the T
M
test statistic is -1.83, which implies the selection odds
ratio must be at least e
1:83
= 6:23 before the signicance of the test result is lost. The
sensitivity analyses based on the other two test statistics give similar results (Figure 2).
Fifth, an estimation-based sensitivity analysis can be carried out (Figure 3). Suppose
17
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vaccination must lower mean viral load in the always infected by at least 0.2 log
10
to be
considered clinically signicant. The value of  at which the lower 95% condence limit
for 
ACE
() crosses 0.2 is -0.50, corresponding to a \critical" odds ratio of e
0:50
= 1:65.
Sixth, the analyses could be repeated for important subgroups of infected participants.
Seventh, interpretations are made. In this example, a study team might conclude that it
is unlikely that selection bias could fully explain the observed lower viral loads in infected
vaccine recipients, and therefore a genuine viral suppressing eect of vaccine in the always
infected is inferred. However, whether the eect is clinically signicant is inconclusive.
These conclusions would be based on beliefs that a selection bias eect with odds ratio
6:23 or higher is implausible, but a selection odds ratio of 1.65 is not unexpected.
Note that if only the hypothesis H
0
neg
with extreme selection bias 
neg
=  1 had
been tested, then the team would likely not be able to conclude that vaccination reduced
viral load in the always infected (p-value > 0:20, Figure 2). This illustrates the added
value of a continuously-indexed sensitivity analysis.
6. Discussion
Appropriate interpretation of analyses of vaccine eects on viral load is challenging. Two
main reasons are the lack of validation of viral load measures as accurate surrogates for
secondary transmission and disease progression, and the potential for selective eects of
the vaccine to bias inferences. Like HHS, we address the second problem, and extend
their work to provide a method of sensitivity analysis over a continuous range of levels
of putative selective eects. Since the true amount of selection bias may be considerably
less than the worst-case amounts considered by HHS, the methods developed here may
provide for more powerful assessments.
As illustrated in the Example, an observation of lower viral loads in infected vaccine
recipients compared to infected placebo recipients could be caused partly by a causal
18
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viral suppressing eect of vaccine in the always infected principal stratum and partly by
selective vaccine protection against viruses that produce higher viral loads. Both eects
are benecial, and the assessment of the net vaccine eect (in the infected subgroups)
usefully informs about the overall benet of vaccination, and this result should be reported
together with the causal inference for the always infected principal stratum. On the other
hand, for assessing a possible vaccine eect to increase viral load, the inference on the
net vaccine eect could dangerously mislead. Selection bias could create higher viral
loads in infected vaccine recipients compared to infected placebo recipients, i.e., produce
a negative net vaccine eect, even though the vaccine has no adverse causal eect on viral
load and has benecial V E > 0: Therefore, it is crucial to build robustness to selection
bias into assessments of vaccine harm, to protect against a spurious conclusion that could
prevent use of or slow development of a safe and partially eÆcacious vaccine.
Within the framework of FR, this article develops techniques for causal inference in
the always infected principal stratum. Alternatively, causal inference could be made using
a missing data framework that assumes all randomized subjects will eventually become
HIV infected, and thus at some point will have a viral load value. In such an approach, the
viral load is missing in subjects who have not yet been infected by the time of the analysis,
and causal estimands can be dened based on functionals of contrasts of the viral load
distributions for the vaccine and placebo groups. The goal of assessing such estimands is
to compare the viral load distribution between the randomized groups had (contrary to
fact) all subjects been infected during the trial. Rotnitzky and Robins (1997) developed an
inverse probability of censoring weighted estimating equations method that could be used
for causal inference on a mean-dierence version of this estimand. This technique would
model the viral load by a semiparametric conditional mean model with unspecied error
distribution and the infection probability (i.e., the response probability) by a parametric
19
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model. If the hazard rate of infection rather than the binary infection probability was
modeled, then Scharfstein, Rotnitzky, and Robins' (1999) method would apply for making
inference on the same estimand. The advantages of these approaches include that they
minimize modeling assumptions, they can incorporate predictors of the infection risk, and
they can be used for sensitivity analysis of the eect of misspecication of the model for
infection risk. The drawback of any such missing data approach for the present application
is that the causal estimand may not be relevant or interpretable, because it is unrealistic
to suppose that all subjects would eventually be HIV infected. FR criticize use of such a
causal estimand because it uses nonexistent \a priori" counterfactuals. Inferences for the
always infected subpopulation provide interpretable and practical information for vaccine
recipients who become HIV infected despite vaccination.
In addition to HIV vaccine trials, the methods developed here apply to general random-
ized clinical trials, for sensitivity analyses of causal treatment eects in the subpopulation
of subjects who would experience a post-randomization event under either assignment.
Acknowledgements
The authors thank Andrea Rotnitzky, Steve Self, the Associate Editor and referees for
helpful comments. This work was supported by NIH grants AI46703-01 and AI38855.
References
Angrist, J., Imbens, G.W., and Rubin, D.B. (1996). Identication of causal eects using
instrumental variables (with discussion). Journal of the American Statistical Associ-
ation 91, 444-472.
Barouch, D.H., Kunstman, J., Kuroda, M.J., et al. (2002). Eventual AIDS vaccine
failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature
415, 335-339.
20
Hosted by The Berkeley Electronic Press
Burke, D.S. (1992). Human HIV vaccine trials: Does antibody-dependent enhancement
pose a genuine risk? Perspectives in Biology and Medicine 35, 511-530.
Coombs, R.W., Speck, C.E., Hughes, J.P., et al. (1998). Association between culturable
human immunodeciency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in
semen and blood: evidence for compartmentalization of HIV-1 between semen and
blood. Journal of Infectious Diseases 177, 320-330.
D'Agostino, R.B. and Stephens, M.A. (1986). Goodness-of-t techniques. Marcel Dekker,
New York.
Francis, D.P., Gregory, T., McElrath, M.J., et al. (1998). Advancing AIDSVAX to
phase 3: safety, immunogenicity, and plans for phase 3. AIDS Research and Human
Retroviruses 14 Suppl 3, S325-S331.
Frangakis, C.E. and Rubin D.B. (2002). Principal stratication in causal inference. Bio-
metrics 58, 21-29.
Goetghebeur, E., Kenward, M., Molenberghs, G., and Vansteelandt, S. (2000). Inferential
tools for sensitivity analysis and noncompliance in clinical trials. Proceedings of the
Annual Meeting. Indianapolis, Indiana: American Statistical Association.
Halloran, M.E., Haber M.J., and Longini I.M. (1992). Interpretation and estimation of
vaccine eÆcacy under heterogeneity. American Journal of Epidemiology 136, 328-343.
Halloran, M.E. and Struchiner, C.J. (1995). Causal inference in infectious diseases. Epi-
demiology 6, 142-151.
Holland, P. (1986). Statistics and causal inference. Journal of the American Statistical
Association 81, 945-961.
Hudgens, M.G., Hoering, A., and Self, S.G. (2002a). On the analysis of viral load end-
21
http://biostats.bepress.com/uwbiostat/paper208
points in HIV vaccine trials. In: Abstracts of the Fourteenth International AIDS
Conference 2002, Barcelona, Spain, July 2002.
Hudgens, M.G., Hoering, A., and Self, S.G. (2002b). On the analysis of viral load end-
points in HIV vaccine trials. Statistics in Medicine: in press
Mascola, J.R., Mathieson, B.J., Zack, P.M., Walker, M.C., Halstead, S.B., and Burke,
D.S. (1993). Summary report: workshop on the potential risks of antibody-dependent
enhancement in human HIV vaccine trials. AIDS Research and Human Retroviruses
9, 1175-1184.
Mellors, J.W., Munoz, A., Giorgi, J.V., et al. (1997). Plasma viral load and CD4+
lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine
126, 946-954.
Nabel, G.J. (2001). Challenges and opportunities for development of an AIDS vaccine.
Nature 410, 1002-1007.
Quinn, T.C., Wawer, M.J., Sewankambo, N., et al. (2000). Viral load and heterosex-
ual transmission of human immunodeciency virus type 1. New England Journal of
Medicine 342, 921-929.
Rida, W., Fast, P., Ho, R., and Fleming, T.R. (1997). Intermediate-sized trials for the
evaluation of HIV vaccine candidates: a workshop summary. Journal of Acquired
Immune Deciency Syndrome 16, 195-203.
Rida, W.N. and Lawrence, D.L. (1995). Prophylactic HIV vaccine trials. In: Finkelstein
DM, Schoenfeld DA, eds. AIDS clinical trials: Guidelines for design and analysis.
Wiley-Liss, New York, 319-348.
Robins, J.M. and Greenland, S. (1992). Identiability and exchangeability of direct and
22
Hosted by The Berkeley Electronic Press
indirect eects. Epidemiology 3, 143-155.
Rosenbaum, P.R. (1984). The consequences of adjustment for a concomitant variable
that has been aected by the treatment. The Journal of the Royal Statistical Society,
Series A 147, 656-666.
Rosenbaum, P.R. and Rubin, D.B. (1983). Assessing sensitivity to an unobserved binary
covariate in an observational study with binary outcome. The Journal of the Royal
Statistical Society, Series B 45, 212-218.
Rotnitzky, A. and Robins, J. (1997). Analysis of semi-parametric regression models with
non-ignorable non-response. Biometrics 16, 81-102.
Rubin, D.B. (1974). Estimating causal eects of treatments in randomized and nonran-
domized studies. Journal of Educational Psychology 66, 688-701.
Rubin, D.B. (1978). Bayesian inference for causal eects. Annals of Statistics 6, 34-58.
Rubin, D.B. (2000). Comment on \Causal inference without counterfactuals," by A.P.
Dawid. Journal of the American Statistical Association 95, 435-437.
Scharfstein, D.O., Rotnitzky, A., and Robins, J.M. (1999). Adjusting for nonignorable
drop-out using semiparametric nonresponse models. Journal of the American Statis-
tical Association 94, 1096-1146.
Shiver, J.W., Fu, T.-M., Chen, L., et al. (2002). Replication-incompetent adenoviral
vaccine vector elicits eective anti-immunodeciency virus immunity. Nature 415,
331-335.
Sterling, T.R., Vlahov, D., Astemborski, J., Hoover, D.R., Margolick, J.B., and Quinn,
T.C. (2001). Initial plasma HIV-1 RNA levels and progression to AIDS in women and
men. New England Journal of Medicine 344, 720-725.
23
http://biostats.bepress.com/uwbiostat/paper208
Table 1. For the two randomization assignments Z
i
= v; p and infection outcomes
S
obs
i
 S
i
(Z
i
) = 0; 1, the table indicates the basic principal stratum or strata to which
the subjects belong, and the information available on the potential viral loads Y
i
(v) and
Y
i
(p). Note that Y
i
(Z) is dened if and only if S
i
(Z) = 1; Z = v; p; and the principal
strata of uninfected placebo recipients and of infected vaccine recipients are known by
assumption A2.
Randomiz. Observed
Assignm. Infection Principal Stratum fS
i
(v); S
i
(p)g and
Z
i
Status S
obs
i
Information on Potential Viral Loads Y
i
(v); Y
i
(p)
vaccine uninfected Protected or Never-infected
fS
i
(v) = 0; S
i
(p) = 1g fS
i
(v) = 0; S
i
(p) = 0g
Y
i
(v) undened Y
i
(v) undened
Y
i
(p) unobserved Y
i
(p) undened
placebo uninfected Never-infected
fS
i
(v) = 1; S
i
(p) = 0g fS
i
(v) = 0; S
i
(p) = 0g
(empty set by A2) Y
i
(v) undened
Y
i
(p) undened
vaccine infected Always-infected
fS
i
(v) = 1; S
i
(p) = 0g fS
i
(v) = 1; S
i
(p) = 1g
(empty set by A2) Y
i
(v) observed
Y
i
(p) unobserved
placebo infected Protected or Always-infected
fS
i
(v) = 0; S
i
(p) = 1g fS
i
(v) = 1; S
i
(p) = 1g
Y
i
(v) undened Y
i
(v) unobserved
Y
i
(p) observed Y
i
(p) observed
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Table 2. Power  100% for detecting a 0, 1/3, and 1/2 log
10
mean-shift alternative, over
and above any selection bias induced by the true ; based on a 1-sided 5% level test
Nonparametric Kolmogorov- Anderson-
True Presumed Mean Smirnov Darling
  0 1/3 1/2 0 1/3 1/2 0 1/3 1/2
V E = 30%
0 0 4.8 73.8 96.8 5.4 69.0 91.2 4.0 72.0 94.4
0 1 3.2 49.8 82.0 3.0 44.8 78.2 2.4 46.8 79.6
0 1 0.2 15.8 36.0 0.8 16.8 37.6 0.2 15.4 33.6
1 0 14.6 91.8 99.8 15.6 85.4 97.8 14.4 90.2 99.2
1 1 5.8 67.6 94.6 7.2 63.4 90.8 5.4 65.4 94.0
1 1 1.8 26.0 52.2 1.4 27.6 51.8 1.6 25.8 48.8
1 0 69.6 100 100 76.2 100 100 79.8 100 100
1 1 37.4 95.8 100 42.6 97.0 100 45.8 97.4 100
1 1 8.8 55.0 83.2 12.0 55.2 82.4 10.8 57.2 86.2
V E = 50%
0 0 6.6 70.0 93.2 5.8 63.8 89.8 5.8 66.4 92.6
0 1 1.0 30.6 64.2 0.4 25.8 58.0 0.2 26.6 61.2
0 1 0.2 3.4 10.2 0.4 3.6 9.0 0.2 2.8 7.4
1 0 25.8 92.2 99.0 24.8 87.4 99.0 24.0 91.0 99.2
1 1 5.0 62.4 88.2 5.8 57.2 84.2 4.2 60.6 87.8
1 1 0.4 9.8 30.6 0.2 8.6 25.0 0.2 8.2 24.6
1 0 94.8 100 100 97.2 100 100 97.6 100 100
1 1 56.8 99.2 100 72.6 99.8 100 69.0 99.6 100
1 1 5.2 59.2 84.2 6.0 55.6 79.4 6.4 57.8 82.0
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Figure Legends
Figure 1. The upper panel shows plots of the density of Y
i
(p) for subjects infected under
randomization to placebo fS
i
(p) = 1g (total area) partitioned into the subdensity for
\protected" subjects not infected under randomization to vaccine fS
i
(v) = 0; S
i
(p) = 1g
(hatchmarked area = V E) and the subdensity for subjects \always infected" under ran-
domization to either vaccine or placebo fS
i
(v) = 1; S
i
(p) = 1g (unshaded area = 1 V E).
Using model (6) with  =  1; 1; 0; 1; or 1; the 5 panels reect dierent assumptions
about how the vaccine relative risk w(yj; ) = RR(y) = Pr(S
i
(v) = 1jY
i
(p) = y; S
i
(p) =
1) depends on the potential viral load (PVL) Y
i
(p) = y for subjects infected under ran-
domization to placebo. The lower panel shows corresponding plots of the logistic weight
function w(yj; ). The hatchmarked areas equal V E = 0:30; and  was calculated from
1  V E =
R
1
 1
w(zj; )dF
(p)
(z) with F
(p)
() given a normal distribution.
Figure 2. Based on the nonparametric mean-based, Anderson-Darling-type, and Kolmogorov-
Smirnov-type test statistics, the gure shows the 1-sided bootstrap p-value plotted as a
function of the selection bias odds ratio OR = e
 
= e
 
neg
; e

is the odds ratio of infec-
tion under randomization to vaccine given infection under randomization to placebo with
viral load y versus with viral load y   1. If the magnitude of selection bias is believed
to be less than OR = e
1:83
= 6:23; then a signicant causal eect of vaccination to lower
viral load in the always infected principal stratum can be inferred.
Figure 3. Point estimates
b

ACE
() =  T
M
(bold line) and bootstrap 95% condence in-
tervals (dotted lines) for the average causal eect of vaccine 
ACE
() =
R
1
 1
yfdF
alw:inf
(p)
(y) 
dF
alw:inf
(v)
(y)g in the always infected principal stratum as a function of the selection bias
odds ratio OR = e
 
pos
(left side of 0) and of OR = e
 
neg
(right side of 0); e

is the odds
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ratio of infection under randomization to vaccine given infection under randomization to
placebo with viral load y versus with viral load y 1. If the magnitude of selection bias is
believed to be less than OR = e
0:50
= 1:65; then a signicant causal eect of vaccination
to lower the mean viral load by at least 0.2 log
10
in the always infected principal stratum
can be inferred.
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